Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8
Zhiqiang Sun, Bulian Deng, Zichao Yang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 239, pp. 114544-114544
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 57
HDAC-targeting epigenetic modulators for cancer immunotherapy
Binbin Cheng, Wei Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 35
Pathological Role of HDAC8: Cancer and Beyond
Ji Yoon Kim, Hayoung Cho, Jung Yoo, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3161-3161
Open Access | Times Cited: 49
Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity
Laura Sinatra, Jing Yang, Julian Schliehe‐Diecks, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16860-16878
Open Access | Times Cited: 42
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 27
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 26
Degraders in epigenetic therapy: PROTACs and beyond
Xing‐Jie Dai, Shi‐Kun Ji, Meng‐Jie Fu, et al.
Theranostics (2024) Vol. 14, Iss. 4, pp. 1464-1499
Open Access | Times Cited: 11
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 9
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10014-10014
Open Access | Times Cited: 30
Discovery of highly potent HDAC8 PROTACs with anti-tumor activity
Chunlong Zhao, Deng Chen, Feng‐Zhi Suo, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106546-106546
Open Access | Times Cited: 16
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation
Yufeng Xiao, Seth Hale, Nikee Awasthee, et al.
Cell chemical biology (2023) Vol. 30, Iss. 11, pp. 1421-1435.e12
Open Access | Times Cited: 14
Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects
Zhiqiang Sun, Chenglong Xu, Jinmei Cheng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13067-13088
Closed Access | Times Cited: 6
Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8
Yufeng Xiao, Nikee Awasthee, Yi Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 12784-12806
Closed Access | Times Cited: 5
Overview of Class I HDAC Modulators: Inhibitors and Degraders
Ziqian Huang, Limei Zeng, Binbin Cheng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116696-116696
Closed Access | Times Cited: 5
Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors
Chunlong Zhao, Jianqiu Zhang, Hangyu Zhou, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 14016-14039
Open Access | Times Cited: 4
Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function
Yuheng Jin, Xuxin Qi, Xiaoli Yu, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
PROTAC chemical probes for histone deacetylase enzymes
Urvashi Patel, Joshua P. Smalley, James T. Hodgkinson
RSC Chemical Biology (2023) Vol. 4, Iss. 9, pp. 623-634
Open Access | Times Cited: 9
HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry
S. Rajaraman, Ranjani Balakrishnan, Dhruv Deshmukh, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 10, pp. 885-908
Closed Access | Times Cited: 6
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues
Marta Pichlak, Tomasz Sobierajski, K. M. Błażewska, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 4
Exploring Degradation of Intrinsically Disordered Protein Yes-Associated Protein Induced by Proteolysis TArgeting Chimeras
Chen Zhou, Chunbao Sun, Miao Huang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 15168-15198
Closed Access | Times Cited: 1
Exploring Degradation of Intrinsically Disordered Protein YAP induced by PROTACs
Chen Zhou, Chunbao Sun, Liya Pi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Probing Class I Histone Deacetylases (Hdac) with Proteolysis Targeting Chimera (Protac) for the Development of Highly Potent and Selective Degraders
Hany S. Ibrahim, Menglu Guo, Sebastian Hilscher, et al.
(2024)
Closed Access
Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders
Hany S. Ibrahim, Menglu Guo, Sebatian Hilscher, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107887-107887
Open Access
HDAC8 as a target in drug discovery: function, structure and design
Qianlong Zhao, Hongyan Liu, Jie Peng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116972-116972
Closed Access
Nitrogen-containing heterocycles as important scaffold for selective and potent HDAC8 inhibition: a step towards effective, non-toxic and selective HDAC8 inhibitor discovery
Samima Khatun, Rakibul Islam, Sk. Abdul Amin, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-19
Closed Access
Page 1 - Next Page

Scroll to top